XML 68 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Asset Acquisition and License Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Sep. 30, 2016
Dec. 31, 2015
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Asset Acquisition [Line Items]                  
Restricted cash (SRX Cardio) $ 172,000 $ 178,000     $ 30,000 $ 172,000 $ 30,000 $ 172,000 $ 173,000
Net Income (loss) attributable to noncontrolling interest (SRX Cardio)         223,000 $ 240,000 (109,000) 195,000  
Milestone payment on regulatory approval               $ 5,000,000  
Millennium Pharmaceuticals, Inc | United States                  
Asset Acquisition [Line Items]                  
Milestone payment on regulatory approval $ 5,000,000                
Millennium Pharmaceuticals, Inc | Research and Development Expense                  
Asset Acquisition [Line Items]                  
Milestone payment   $ 2,000,000              
Millennium Pharmaceuticals, Inc | Cost of Sales | United States                  
Asset Acquisition [Line Items]                  
Finite-lived intangible assets, amortization expenses         100,000   $ 300,000    
Maximum | Millennium Pharmaceuticals, Inc                  
Asset Acquisition [Line Items]                  
Percentage of royalty on product sales             8.00%    
Minimum | Millennium Pharmaceuticals, Inc                  
Asset Acquisition [Line Items]                  
Percentage of royalty on product sales             2.00%    
SRX Cardio                  
Asset Acquisition [Line Items]                  
Variable interest entity, Upfront payment     $ 2,200,000 $ 500,000          
Variable interest entity, Terms of arrangements             Accordingly, SRX Cardio is subject to consolidation and we have consolidated the financial statements of SRX Cardio by (a) eliminating all intercompany balances and transactions; and (b) allocating income or loss attributable to the noncontrolling interest in SRX Cardio to net income or loss attributable to noncontrolling interest in our consolidated statement of operations and reflecting noncontrolling interest on our consolidated balance sheet.    
Fair value of indefinite lived intangible assets         3,200,000   $ 3,200,000    
Noncontrolling interest in variable Interest entity         2,900,000   2,900,000    
Restricted cash (SRX Cardio)         $ 30,000   $ 30,000   $ 173,000
SRX Cardio | License Agreement                  
Asset Acquisition [Line Items]                  
Notice period for agreement termination     90 days            
SRX Cardio | License Agreement | Maximum                  
Asset Acquisition [Line Items]                  
Research and development milestone payment obligation     $ 152,500,000            
Percentage of royalties on worldwide net sales, obligated to pay     6.00%            
SRX Cardio | License Agreement | Minimum                  
Asset Acquisition [Line Items]                  
Percentage of royalties on worldwide net sales, obligated to pay     2.00%